ERBB2 and glioblastoma: Early-phase clinical translation of CAR T cells against glioblastoma targeting single antigens such as epidermal growth factor receptor variant III (EGFRvIII), human epidermal growth factor receptor 2 (HER2), or interleukin (IL)-13 receptor alpha 2 (IL13Rα2) has shown a favorable safety profile but only modest therapeutic activity.7